Name | Title | Contact Details |
---|
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
VitaKey`s technology platform provides for a wide range of advanced encapsulations triggered by desired pH levels or other stimuli. Our technology delivers targeted and time-controlled release of micronutrients, vitamins, probiotics, nutraceuticals, antioxidants, proteins and amino acids, and flavors, as well as excellent bioavailability.
The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we`re looking for the best ideas and the brightest minds to carry out each process. We`re committed to diversity in all its forms.